Shizuoka, Japan

Kouichi Kuno

This inventor holds 2 USPTO granted patents. Top assignee: Toyo Jozo Kabushiki Kaisha. Active years: 1992.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Kouichi Kuno: Innovator in Aldose Reductase Inhibitors

Introduction

Kouichi Kuno is a notable inventor based in Shizuoka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of aldose reductase inhibitors. His work is crucial for advancing treatments for diabetic complications.

Latest Patents

Kuno holds 2 patents related to aldose reductase inhibitors. His first patent describes a compound that includes a formula with lower alkyl or cyclohexylmethyl as effective components. This compound exhibits superior aldose reductase inhibiting activity and high stability, making it useful for preventing and treating diabetic complications. His second patent focuses on biphenyl-5,5'-bis-alkanoic acid derivatives, which also demonstrate effective aldose reductase inhibition and stability, further contributing to diabetes therapy.

Career Highlights

Kouichi Kuno is associated with Toyo Jozo Kabushiki Kaisha, where he continues to innovate in the pharmaceutical sector. His research has led to advancements that are vital for improving patient outcomes in diabetes management.

Collaborations

Kuno has collaborated with notable colleagues such as Yukio Suzuki and Motoshi Shoda. Their combined expertise has fostered a productive research environment, enhancing the development of effective therapeutic solutions.

Conclusion

Kouichi Kuno's contributions to the field of aldose reductase inhibitors highlight his role as a key innovator in pharmaceutical research. His patents and collaborations reflect a commitment to improving health outcomes for individuals with diabetes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…